Q (sonnet-5.5): Are TP53 mutations clinically actionable?

═ answer (success)
I can't give a clinical actionability call. This is a research tool, and I can't offer clinical advice. I also didn't query cBioPortal data for this answer, so what follows is general background and not something I computed from the data.

- **Current status:** TP53 mutations are generally regarded as not directly actionable. No targeted therapy is broadly approved on the basis of a TP53 mutation alone. Efforts to restore or reactivate mutant p53 have mostly stayed in clinical trials.
- **Where TP53 status still matters:** It is often used as a prognostic or risk-stratification marker, and in some diseases it feeds into classification or trial eligibility. This depends on the cancer type, so check current guidelines and the OncoKB knowledge base for specifics.
- **What cBioPortal shows:** It displays the mutations, and for studies that include OncoKB annotations it shows oncogenicity and level-of-evidence icons. Use the Mutations tab or OncoPrint in the portal to see those annotations for a specific variant. I haven't confirmed which studies here carry them.

I can pull TP53 mutation frequencies for a particular cancer type or study and link you to the relevant cBioPortal views. Tell me which cohort you want.